Carpooled with Chul Kim to the airport on way to #TexasLung24 ! Happy now Stephen V Liu, MD? 🤣

Congratulations to Dr. Jason Westin for becoming the ASCP Advocate of the Year! - Fernando Diaz, MD
Jason Westin, MD FACP
ASCO ASCOTECAG Amanda Nizam, MD Ana I. Velázquez Mañana, MD MSc (she/her/ella) karan jatwani Joshua Reuss

#ASCO #Cancer #OncoDaily #Oncology #ASCO AdvocacySummit

oncodaily.com/49987.html

Thank you ASCO for naming me a 2023 Advocacy Champion at the ASCO Advocacy Summit - Joshua Reuss
Amanda Nizam, MD Ana I. Velázquez Mañana, MD MSc (she/her/ella) Sumanta K. Pal, MD, FASCO Fernando Diaz, MD

#AdvocacyChampion #ASCO #OncoDaily #Oncology #Cancer

oncodaily.com/50977.html

The 2024 Texas Lung Cancer Conference starts tomorrow! Looking forward to chairing this meeting with Dr. Tina Cascone. Follow #TexasLung24 for all the meeting updates TLC Conference!
IDEOlogy Health IASLC #LCSM

Thank you ASCO for naming me a 2023 Advocacy Champion at the #ASCOAdvocacySummit along w/ incredible colleagues & friends Amanda Nizam, MD Ana I. Velázquez Mañana, MD MSc (she/her/ella) Sumanta K. Pal, MD, FASCO Fernando Diaz, MD et al. While unable to join this year's summit, I am proud to continue to fight to improve cancer care!

Congratulations to Dr. Jason Westin Jason Westin, MD FACP for becoming the ASCP Advocate of the Year! 🏆

I'm also thrilled to see ASCO TECAG members Amanda Nizam, MD in the President's Circle 🎉, Ana I. Velázquez Mañana, MD MSc (she/her/ella) karan jatwani and myself in the Speaker's Circle, and Joshua Reuss in the…

Very helpful review of ADC toxicities with Beth Sandy at #PLCClive24 including pneumonitis, nausea, stomatitis. Maintain high suspicion for pneumonitis - though not common, it is important to recognize early.

#PLCClive24 Dr. Christine Bestvina helps discuss many of the emerging antibody drug conjugates including ADCs targeting HER2, HER3, and MET with many more under investigation. MedscapeLIVE

Dr. Sandip Patel MD discusses Trop2 ADCs at #PLCClive24 . Sacituzumab govitecan and datopotamab deruxtecan both with some activity but how do they compare to docetaxel? Datopotamab with a good signal in non-squamous. No clear biomarker yet. MedscapeLIVE

Took a photo of our multidisciplinary clinic team for yesterday’s session to share with first graders tomorrow for Career Day.

Teamwork makes the dream work!

Georgetown Lombardi

Dr. Joshua Reuss joins #PLCClive24 to demystify antibody drug conjugates and explain the significance of each component: antibody (and antigen), linker, and payload as well as overarching principles like internalization and bystander effects. MedscapeLIVE

First time watching his father give a presentation at #PLCClive24 ! Unfortunately seemed more interested in his blocks than the mechanism of action of antibody drug conjugates.

Phase III ALINA trial of adjuvant alectinib for resected stage Ib-IIIA (AJCC v7) #ALK NSCLC now NEJM. Compared 2y of alectinib to chemotherapy. Alectinib improved DFS (HR 0.24) with 2y DFS rate 94% vs 63%! CNS DFS 0.22, OS pending. Standard of care IMO.

nejm.org/doi/full/10.10…

Press release: phase III ADRIATIC study of durvalumab after chemoradiation for limited stage #SCLC improves both PFS and OS. Follows the PACIFIC approach, randomizing after definitive chemoradiation. Await data on durva + tremelimumab arm. #LCSM

astrazeneca.com/media-centre/p…

Just out CA: A Cancer Journal for Clinicians

'Global cancer statistics 2022: #GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries'

Global maps showing the most common type of cancer mortality among men and women 👇

Lung cancer shown in Blue

American Cancer Society

Check out our podcast on the importance of biomarker testing in the treatment of advanced NSCLC

Collaborating with the one and only Dr. Fred R. Hirsch was a remarkable experience!

bit.ly/3vtGAfU

#LCSM

In this #ASCO Educational Book📕 we summarize in EGFR mut🫁:
✏️New EGFR TKI options in early stage
✏️New options in metastatic setting
✏️Mechanisms of acquired resistance and new drugs 🧬
online at ascopubs.org/journal/edbk
Thanks to Stephanie Saw Xiuning Le MD PhD Lizza Hendriks

Dr. Antoinette Wozniak with an EXCELLENT discussion of the exploding peri-operative space in resectable NSCLC at IASLC Best of #TTLC24 webinar. What will push us toward neoadj vs perioperative? pCR? MRD? impt research questions that need answering.

Best of TTLC webinar is live now!!! Come join us! Kaushal Parikh Amit Kulkarni Antoinette Wozniak. #IASLC #LCSM

March has been fruitful and rewarding, as we launched two IITs of ADC back to back!

1. #Vobramitamab duocarmazine (B7-H3 ADC) for ES-SCLC, inclusive of pts with transformed SCLC (NCT06227546)

2. #Sacituzumab govitecan for thymic epithelial tumors (NCT06248515)

Georgetown Lombardi